Twist Bioscience Corporation (TWST) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 120.25M USD | Liabilities, Current |
| Cash and equivalents | 117.44M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 65.06M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 35.16M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $120.25M | $117.44M | (m) | $65.06M | $35.16M | (m) |
| 2026-03-31 | (m) | $119.98M | $122.67M | (m) | $64.15M | $33.52M | (m) |
| 2025-12-31 | (m) | $80.44M | $148.59M | (m) | $50.06M | $32.92M | (m) |
| 2025-09-30 | (m) | $91.41M | $183.05M | (m) | $57.02M | $28.31M | (m) |
| 2025-06-30 | (m) | $87.07M | $201.37M | (m) | $49.85M | $25.94M | (m) |
| 2025-03-31 | (m) | $74.98M | $210.44M | (m) | $49.95M | $20.86M | (m) |
| 2024-12-31 | (m) | $69.65M | $221.40M | (m) | $39.31M | $23.52M | (m) |
| 2024-09-30 | (m) | $71.01M | $226.32M | (m) | $34.90M | $24.08M | (m) |
| 2024-06-30 | (m) | $73.76M | $239.14M | (m) | $31.99M | $28.48M | (m) |
| 2024-03-31 | (m) | $67.49M | $243.35M | (m) | $35.99M | $30.38M | (m) |
| 2023-12-31 | (m) | $65.23M | $266.27M | (m) | $35.35M | $30.86M | (m) |
| 2023-09-30 | (m) | $73.32M | $286.47M | (m) | $44.06M | $32.06M | (m) |
| 2023-06-30 | (m) | $72.82M | $307.46M | (m) | $42.58M | $36.35M | (m) |
| 2023-03-31 | (m) | $72.11M | $315.20M | (m) | $48.19M | $39.92M | (m) |
| 2022-12-31 | (m) | $83.84M | $316.68M | (m) | $44.44M | $44.60M | (m) |
| 2022-09-30 | (m) | $90.66M | $378.69M | (m) | $40.29M | $39.31M | (m) |
| 2022-06-30 | (m) | $92.69M | $376.25M | (m) | $41.20M | $43.02M | (m) |
| 2022-03-31 | (m) | $84.63M | $407.63M | (m) | $34.88M | $44.59M | (m) |
| 2021-12-31 | (m) | $80.03M | $191.62M | (m) | $32.87M | $40.24M | (m) |
| 2021-09-30 | (m) | $63.05M | $465.83M | (m) | $28.55M | $31.80M | (m) |
| 2021-06-30 | (m) | $54.83M | $475.28M | (m) | $28.12M | $21.22M | (m) |
| 2021-03-31 | (m) | $40.44M | $399.33M | (m) | $27.29M | $15.84M | (m) |
| 2020-12-31 | (m) | $37.10M | $348.79M | (m) | $25.49M | $13.41M | (m) |
| 2020-09-30 | (m) | $36.03M | $93.67M | (m) | $26.38M | $12.29M | (m) |
| 2020-06-30 | (m) | $31.38M | $207.85M | (m) | $13.35M | $13.16M | (m) |
| 2020-03-31 | (m) | $30.21M | $184.40M | (m) | $14.83M | $10.76M | (m) |
| 2019-12-31 | (m) | $57.84M | $26.03M | (m) | $13.05M | $7.42M | (m) |
| 2019-09-30 | (m) | $30.35M | $46.73M | (m) | $12.10M | $7.33M | (m) |
| 2019-06-30 | (m) | $25.45M | $68.21M | (m) | $11.70M | $5.50M | (m) |
| 2019-03-31 | (m) | $18.58M | $28.69M | (m) | $8.00M | $4.45M | (m) |
| 2018-12-31 | (m) | $19.00M | $66.46M | (m) | $6.98M | $5.56M | (m) |
| 2018-09-30 | (m) | $18.54M | $80.76M | (m) | $5.42M | $6.03M | (m) |
| 2017-09-30 | (m) | (m) | $31.23M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |